Thalassaemia

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
Clinical News

TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders

A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
WHO SEARO Publishes Desk Review of Haemoglobinopathies in the South-East Asia Region
NOVITÀ

WHO SEARO Publishes Desk Review of Haemoglobinopathies in the South-East Asia Region

In an effort to understand the prevalence of thalassaemic syndromes and the existent blood supply system available within each country of the South-East Asia Region, the WHO Regional Office for…
TIF Presents The Federation’s Annual Report For 2020
NOVITÀ

TIF Presents The Federation’s Annual Report For 2020

“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…
Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF
NOVITÀ

Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF

The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…
Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini
Member News

Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini

The past decade has witnessed path-breaking advances with regard to novel therapeutic approaches of thalassaemia and, most significantly, phenomenal developments made in the direction of gene therapy of β- thalassaemia…
Clinical Trials Update: The June 2021 Edition
Clinical News

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
TIF Is Actively Participating In The 26th EHA Annual Congress
Clinical News

TIF Is Actively Participating In The 26th EHA Annual Congress

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
WORLD BLOOD DONOR DAY 2021: Give blood and keep the world beating
Blood Donation

WORLD BLOOD DONOR DAY 2021: Give blood and keep the world beating

An Overview: Every year, on 14 June, countries around the world celebrate World Blood Donor Day (WBDD). The event serves to thank voluntary, unpaid blood donors for their life-saving gifts…
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
Clinical News

Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies

bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
Back to top button